Evidence map›Paper›PMID 42122269›Full record

ArticleCancers2026

Glycosylated Chitosan Inhibits Pancreatic Cancer Metastasis by Blocking the Caveolin Signaling Pathway.

Yong Li, Jacob Paul Adams, Jingxuan Yang, Abigael P Williams, Min Li, Joanne Tuohy, Wei R Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yong LiTianjin Key Laboratory of Cancer Prevention and Therapy, Interventional Therapy Department, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Jacob Paul AdamsStephenson School of Biomedical Engineering, The University of Oklahoma, Norman, OK 73019, USA.
Jingxuan YangHematology-Oncology, Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.ORCID 0000-0003-3265-161X
Abigael P WilliamsStephenson School of Biomedical Engineering, The University of Oklahoma, Norman, OK 73019, USA.ORCID 0009-0005-6667-4053
Min LiHematology-Oncology, Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Joanne TuohyVA-MD College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA.ORCID 0000-0003-1516-3841
Wei R ChenStephenson School of Biomedical Engineering, The University of Oklahoma, Norman, OK 73019, USA.

Funding

Foundation for the National Institutes of Health R01CA138701Foundation for the National Institutes of Health R01CA186338Foundation for the National Institutes of Health R01CA203108Foundation for the National Institutes of Health R01CA205348Foundation for the National Institutes of Health R01CA269897
6 · The paper itself

Abstract

BACKGROUND AND

objectivesPancreatic cancer is highly metastatic, and metastasis is the main cause of cancer-related deaths. Therefore, finding methods to inhibit pancreatic cancer metastasis has important clinical value.

methods

resultsHere, we found that GC can inhibit the migration of pancreatic cancer cells through interactions with caveolin-1 (Cav-1). The fluorescence of GC-FITC on the cell surface overlaps with Cav-1-Red, is enhanced by adCav-1, and is weakened by siCav-1, indicating that the localization of GC depends on Cav-1. GC inhibits the migration of malignant cells by blocking the signal transduction of Cav-1 and its downstream molecules. In an orthotopic pancreatic tumor model, GC can inhibit tumor metastasis in tumor-bearing mice.

conclusionsThese results demonstrate GC's capacity to act as a partner in pancreatic cancer therapy and indicate future directions for metastatic cancer therapy.

Indexed as

caveolin-1GCimmunotherapylaser therapymetastasispancreatic cancer

Identifiers

PMID42122269
PMCPMC13162701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.